These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 11570093)
1. From grapefruit juice to ritonavir. TreatmentUpdate; 2001; 12(12):5-6. PubMed ID: 11570093 [No Abstract] [Full Text] [Related]
2. Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg. Ananworanich J; Siangphoe U; Mahanontharit A; Hill A; Hirschel B; Ruxrungtham K Antivir Ther; 2004 Dec; 9(6):1035-6. PubMed ID: 15651763 [No Abstract] [Full Text] [Related]
3. Saquinavir/low-dose ritonavir: its use in HIV infection. Johnson M; Peters B AIDS Rev; 2003; 5(1):44-51. PubMed ID: 12875107 [TBL] [Abstract][Full Text] [Related]
4. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850 [TBL] [Abstract][Full Text] [Related]
5. FDA notifications. Potential serious effect of combination saquinavir-ritonavir. AIDS Alert; 2010 Apr; 25(4):45-6. PubMed ID: 20564774 [No Abstract] [Full Text] [Related]
6. Searching for the right dose of ritonavir-saquinavir. TreatmentUpdate; 2001 Sep; 13(5):3. PubMed ID: 11768860 [No Abstract] [Full Text] [Related]
7. Saquinavir plus ritonavir reduce viral load by 99.9 percent. Vazquez E Posit Aware; 1996; 7(6):8-9. PubMed ID: 11363983 [TBL] [Abstract][Full Text] [Related]
9. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study). Lamotte C; Landman R; Peytavin G; Mentre F; Gerbe J; Brun-Vezinet F; Boue F; Spiridon G; Valantin MA; Michelet C; Farinotti R; Yeni P Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187 [TBL] [Abstract][Full Text] [Related]
10. The use of saquinavir/ritonavir 1000/100 mg twice daily in patients with tuberculosis receiving rifampin. Losso MH; Lourtau LD; Toibaro JJ; Saenz C; González C Antivir Ther; 2004 Dec; 9(6):1031-3. PubMed ID: 15651762 [No Abstract] [Full Text] [Related]
11. A patient's guide to protease inhibitors. Elperin A; Sax P AIDS Clin Care; 1996 Oct; 8(10):83-4. PubMed ID: 11363988 [TBL] [Abstract][Full Text] [Related]
12. Combined protease results continue to hold up. McGuire S Posit Aware; 1997; 8(1):15. PubMed ID: 11364089 [TBL] [Abstract][Full Text] [Related]
13. Saquinavir/Ritonavir: its evolution and current treatment role. O'Brien WA AIDS Read; 2006 Jan; 16(1):38-44; discussion 43. PubMed ID: 16433471 [TBL] [Abstract][Full Text] [Related]
14. Ketoconazole may improve PI penetration. AIDS Patient Care STDS; 1999 Dec; 13(12):753. PubMed ID: 10743541 [No Abstract] [Full Text] [Related]
15. Drug interactions and protease inhibitor therapy in the treatment of HIV/AIDS. Klaus BD; Grodesky MJ Nurse Pract; 1998 Feb; 23(2):102-4, 106. PubMed ID: 9513221 [No Abstract] [Full Text] [Related]
17. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771 [TBL] [Abstract][Full Text] [Related]
18. A review of low-dose ritonavir in protease inhibitor combination therapy. Cooper CL; van Heeswijk RP; Gallicano K; Cameron DW Clin Infect Dis; 2003 Jun; 36(12):1585-92. PubMed ID: 12802760 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. Boffito M; Back D; Stainsby-Tron M; Hill A; Di Perri G; Moyle G; Nelson M; Tomkins J; Gazzard B; Pozniak A Br J Clin Pharmacol; 2005 Jan; 59(1):38-42. PubMed ID: 15606438 [TBL] [Abstract][Full Text] [Related]
20. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B; J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]